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Abstract  
Background: Ledipasvir/sofosbuvir (LDV/SOF) has demonstrated high efficacy, safety and 
tolerability in HCV-infected patients. There is limited data, however, regarding the optimal 
timing of therapy in the context of possible liver transplantation (LT).  
Methods: We compared the cost-effectiveness of 12 weeks of HCV therapy before or after LT or 
nontreatment using a decision analytical microsimulation state-transition model for a simulated 
cohort of 10 000 patients with HCV Genotype 1 or 4 with Child B or C cirrhosis. All model 
parameters regarding the efficacy of therapy, adverse events and the effect of therapy on changes 
in model for endstage liver disease (MELD) scores were derived from the SOLAR-1 and 2 trials. 
The simulations were repeated with 10 000 samples from the parameter distributions. The 
primary outcome was cost (2014 US dollars) per quality adjusted life year (QALY).  
Results: Treatment before LT yielded more QALY for less money than treatment after LT or 
nontreatment. Treatment before LT was cost-effective in 100% of samples at a willingness-to-
pay threshold of $100 000 in the base-case and when the analysis was restricted to Child B alone, 
Child C, or MELD > 15. Treatment before transplant was not cost-effective when MELD was 6-
10. In sensitivity analyses, the MELD after which treatment before transplant was cost-effective 
was 13 and the maximum cost of LDV/SOF therapy at which treatment before LT is cost-
effective is $177,381.  
Conclusion: From a societal perspective, HCV therapy using LDV/SOF with ribavirin prior to 
LT is the most cost-effective strategy for patients with decompensated cirrhosis and MELD > 13. 
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Introduction 
 
 Efficacious, safe and well tolerated direct-acting antiviral therapies have transformed the 
care of patients with hepatitis C (HCV) in a few short years.
1-6
 The standard of care has 
progressed from frequent treatment failures to readily available cures with rare adverse events.
7,8
 
While many important questions remain, 2 of the greatest relate to the cost-effectiveness and 
coverage of treatment
9
 and the timing of therapy for those undergoing evaluation for liver 
transplantation. Given the cost of novel therapies, cures for chronic HCV require a significant 
upfront investment. However, in view of the morbidity of HCV infection, viral eradication has 
been proven reproducibly to be cost-effective from the societal perspective by reducing the need 
for liver transplants, the rate of hepatocellular carcinoma and leading to longer more productive 
lives.
10-12
  
 
 There is limited data, however, to guide clinicians and payers regarding whether to 
initiate anti-HCV therapy before or after transplantation for patients presenting with 
decompensated cirrhosis (Child Class B or C). On one hand, eradication of HCV prior to 
transplant has clear benefits. These include the prevention of recurrent HCV posttransplant, 
which is a major cause of graft-loss.
4,5
 Further, for patients with advanced fibrosis, successful 
HCV treatment prevents the development of liver failure.
13
 As for patients with decompensated 
cirrhosis, there is evidence from the SOLAR-1 and 2 trials of ledipasvir/sofosbuvir (LDV-SOF) 
with ribavirin that viral eradication often leads to a reduction in the patient’s MELD score 
(Model for Endstage Liver Disease) and which could, in some patients, obviate the need for liver 
transplantation.
3
 On the other hand, patients with decompensated cirrhosis are at increased risk 
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of death both before and in the perioperative period. The stage of cirrhotic decompensation, or 
Child Class, may therefore impact the risk-benefit assessment for costly HCV therapy in the 
setting of an uncertain future. For this reason, it is unclear whether pretransplant treatment of 
patients with decompensated cirrhosis will prove cost-effective from the societal perspective. 
 
Herein, we compared the cost-effectiveness of HCV treatment before or after liver 
transplantation in patients with Child B or C cirrhosis using a secondary analysis of the SOLAR-
1 and 2
3
 of LDV-SOF with ribavirin.  
 
Methods  
Model Overview 
 We developed a probabilistic decision analytical microsimulation state-transition model
14
 
using dedicated software (DATA 3.5, TreeAge, Williamstown, MA). The analysis was 
performed according to published guidelines.
15,16
 We simulated a cohort of 10 000 patients with 
decompensated cirrhosis (all Child B or C) who reflected the patients enrolled in the SOLAR-1 
and 2 trials of LDV/SOF and ribavirin.
3
 Study subjects were > 18 years of age with HCV 
genotypes 1 or 4 HCV and were enrolled at 29 US clinical sites. Patients were excluded from 
enrollment if they had human immunodeficiency virus, hepatitis B virus, prior exposure to an 
NS5a inhibitor, hemoglobin < 10 g/dL, platelets < 30 000/mm3, alanine aminotransferase or 
aspartate aminotransferase or alkaline phosphatase > 10 times the upper limit of normal, total 
bilirubin > 10 mg/dL, or creatinine clearance <40 mL/min. All patients received LDV/SOF and 
ribavirin and while they were randomized to receive 12 or 24 weeks of therapy, there were no 
differences in outcome based on duration.
3
 During the SOLAR trials, MELD scores were 
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calculated before, during and after HCV therapy. The pre-post treatment difference in MELD 
was calculated for all patients attaining sustained virologic response (SVR). 
 
 Three treatment strategies were modelled: usual care without HCV therapy, treatment 
before transplant and treatment after transplant. (Figure 1) All patients are Child B or C and 
progress through the model receiving transplants or dying at probabilities based on their MELD 
score. Each patient enters the model with a randomly generated MELD between 6 and 40.The 
odds of transplant are based on a patient’s MELD score at the beginning of a 12 week cycle and 
modelled based on pooled national data (irrespective of transplant region).
17
 While the odds of 
transplant are low for patients with low MELD, as they are Child B and C, there remains a 
statistical probability of transplant during the cycle in view of the risk of further decompensation. 
(Table 1, Figure 2) All patients are eligible for transplant irrespective of the success of treatment 
before transplant. 
 
The modelled treatment duration is 12 weeks, provided either at the outset of the model 
(treat before transplant) or after transplant. Though it is possible that SVR can be achieved if 
therapy is abbreviated by the transplant while the patient’s viral load is negative,4 the model was 
tested both with the simplifying assumption that patients are not transplanted during the course 
of therapy and that patients could be transplanted during therapy. As observed during the 
SOLAR study, pretransplant patients can experience improvements or worsening in their MELD 
scores after therapy. These data were calculated for patients with MELD > and < 15 as well as 
Child B alone or Child C. (Figure 3) Once a patient’s MELD has changed following HCV 
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clearance, it does not progress. Conversely, for patients without SVR and for those who are not 
treated prior to transplant, their MELD advances each cycle based on published estimates. (Table 
1) All patients are assumed to be transplant eligible. The modelled patients do not have 
hepatocellular carcinoma and do not develop cancer during observation as a simplifying 
assumption. Treatment after transplantation is assumed to be provided 3 months postoperatively. 
After transplantation, graft and patient survival is derived from published estimates and is 
affected in part by the presence of active HCV infection. The probability of graft loss is 
increased in patients who have not achieved SVR or for whom treatment was deferred. It is 
assumed that graft loss can be treated with retransplantation only once during this model. 
 
Model Parameters 
 Table 1 details the model parameters as well as their sources. Transition probabilities are 
modelled as beta distributions, costs as gamma distributions (save for the cost of therapy
18
), and 
utilities as triangular distributions. All utilities reflect published estimates derived exclusively 
from patient reported metrics.  There is evidence that successful treatment leads to increases 
patient-reported quality of life (QOL).
6
 We used a conservative estimate that 57% of subjects 
obtaining SVR would experience an 0.026 increase in their reported annual utilities.
19
 For the 
probabilistic sensitivity analyses, the proportion of patients attaining a QOL benefit was 
modelled as a beta distribution and the magnitude of QOL benefit was modelled as a triangular 
distribution 0.026 (0.00 – 0.026).  
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 Given that the probability of SVR is conditional on survival during treatment and we 
modelled the risk of death before the chance of SVR, we performed a secondary analysis of the 
SOLAR data to derive the SVR statistics based on survivors for both pre and posttransplant 
treatment strategies. Similarly, for the sensitivity analyses of outcomes by Child class, we 
determined the changes in MELD after therapy for Child B or Child C patients separately.  
 
Model Procedures  
The goal of this analysis was to model 2 outcomes simultaneously based on the 
generation of discounted costs (2014 US dollars) and discounted quality adjusted life years 
(QALY) that accrue to our cohort over time. There is uncertainty related to any input parameter 
(ie confidence intervals or ranges of values). Each time a patient enters the decision model, they 
experience a unique set of model parameters derived from distributions reflecting the input 
confidence intervals. Therefore, this model is a microsimulation, following the stochastic 
movements of individual subjects through the chances of developing clinical outcomes. It is also 
a probabilistic analytic model which analyzes 10 000 random samples within each parameter’s 
distribution for each simulated patient. The end result is the probability of cost-effectiveness for 
a given strategy in the overall set of simulations.  The primary outcome – cost per QALY – is 
derived from probabilistic sensitivity analyses which were performed using Monte Carlo 
microsimulation of 10 000 patients with 10 000 samples taken from the input parameter 
distributions. 
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Once the relative cost-effectiveness of the strategies is calculated, the results are 
interpreted in the context of society’s willingness-to-pay (WTP) threshold. The WTP threshold is 
the amount of money per person that society is willing to pay to adopt a new clinical strategy for 
an additional QALY over the current acceptable strategy. It is generally considered to be 2-3 
times the individual share of gross domestic product.
20
 We discuss most results in terms of a 
WTP of $100 000 but also assess the probability of cost-effectiveness for each strategy across a 
range of WTP up to $200 000 in ‘cost-acceptability curves’. Finally, we calculated a metric 
called the population ‘expected value of perfect information’ (EVPI). The population EVPI is a 
reflection of the benefit derived from further research and is therefore a measure of the 
uncertainty in this analysis. 
 
Subgroup and Sensitivity Analysis 
We performed 5 subgroup analyses. We reran the model with transition probabilities 
(MELD changes after therapy and SVR rates) specific to 4 subgroups with 1,000 samples from 
the parameter distributions: Child B alone, Child C alone, MELD 6-10, MELD 11-15, and 
MELD > 15 (Table 1, Figure 3). We also re-ran the model with variable transplantation rates in 
order to simulate hypothetical transplant regions with low (MELD 20-25) and high (MELD > 
30) average MELD at the time of transplant. To do so, we modelled the former scenario by 
setting the rate of transplantation at MELD 20-25 and 25-30 equal to the rate at MELD > 30 
(Table 1); high MELD regions were simulated by setting the rate of transplant at MELD < 30 
equal to zero. Each subgroup was re-analyzed in the same fashion as the primary outcome. 
Specific 1-way sensitivity analyses of the base-case included MELD at entry, the cost of therapy 
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and overall SVR, and cost of transplantation. We also assessed the impact of withholding 
allografts from patients with SVR based on the proportion of HCV-positive allografts by 
performing a sensitivity analysis of the reduction in the available donors. 
 
Data Analysis 
The model assumed a 12-week cycle length and terminated after 5 years. We repeated the 
analyses for a 10-year time horizon which did not affect the strategy rankings but focused on 5 
years given that only short-term data is available for the novel therapeutics, particularly in the 
peritransplant setting.  All costs, life-years and utilities were discounted at a rate of 3% per 
annum. Half-cycle correction was performed. All costs were inflated to 2014 values and 
converted to American dollars. Sensitivity analyses were performed for all variables. 
 
The population EVPI is calculated according to previously published procedures.
21
 The 
population with decompensated cirrhosis attributable to hepatitis C is unknown but probably falls 
between 50 000 and 100 000 so we assumed a 10-year lifespan for the modelled therapy and 
75,000 applicable patients per year. 
 
Results 
 The results derived from base-case as well as the 4 disease-state substrata are detailed in 
Table 2. In the base-case, the treat before transplant strategy yields more QALYs at a lower cost 
compared to the other strategies and is therefore a dominant strategy. Both treatment strategies 
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yield more QALYs than the nontreatment arm. Nontreatment is less costly in 4 substrata: 
patients with MELD 6-10, MELD 11-15, patients who are Child B alone or patients who are 
Child C alone. Treatment before transplant offers more QALYs in each of the disease-state strata 
save for patients with MELD > 15 where treatment after transplant provides higher QALYs. 
Treatment before transplant is the most cost effective strategy within a WTP threshold of 
$100 000 per additional QALY in all cases save for patients with initial MELD 6-10. For patients 
with a MELD of 6-10 at study entry, treatment before transplant is associated with an 
incremental cost > $100 000/QALY over nontreatment and is therefore not cost-effective.  
 
 The effect of a given region’s average MELD at the time of transplant was explored with 
2 subgroup analyses. (Table 3) First, we simulated a hypothetical region where the rate of 
transplantation with MELD > 20 was set as the same for MELD > 30 (ie 0.88, range 0.70-1). 
22
 
In this context, treatment before transplantation is the dominant strategy, cost-effective in 100% 
of simulations, by producing more QALY for lower cost than treatment after transplant or no 
treatment at all. Second, we simulated a hypothetical region where transplantation only occurred 
with MELD > 30. Here, no treatment was cost-effective at the lowest WTP thresholds. However, 
because treatment before transplant produced the most QALY for a marginal incremental cost 
($27,878 per additional QALY), it was the most cost-effective strategy overall at contemporary 
WTP thresholds.  
 
 Cost-acceptability curves were generated to capture the results of each probabilistic 
sensitivity analysis (Figure 4). The proportion of simulations where a given strategy is cost-
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effective was assessed for the range WTP thresholds from $0 to $200 000 for the base-case and 
each disease-state sub-strata. In the base-case, treatment before transplantation was cost-effective 
in the majority of simulations with non-treatment being the most cost-effective in a minority 
(<1%) of simulations up to a WTP threshold of $100 000. After at WTP threshold of $100 000, 
treatment before transplantation is the most cost-effective strategy in the vast majority of 
simulations for the base-case and each Child Class, B or C. Treatment before transplant is cost-
effective at all WTP for patients with MELD > 15. It is cost-effective in the majority of 
simulations for patients with MELD 11-15 beginning at a WTP of $70 000. For patients with 
MELD 6-10, however, treatment before transplant is the most cost-effective strategy in the 
majority of simulations at WTP of $130 000. Finally, treatment before transplantation was the 
most cost-effective strategy at all WTP > $30 000 irrespective effect of a region’s average 
MELD at transplantation.   
 
There were 5 notable results from additional 1-way sensitivity analyses in the base-case. 
First, the MELD score at which treatment before transplant becomes the most cost-effective 
strategy is 13. Second, the pretransplant SVR at which treatment before transplant becomes more 
cost-effective than nontreatment is 49.2%. Third, the maximum cost of therapy for which 
treatment before and after transplantation becomes more cost-saving than nontreatment are 
$177,381 and $57,850, respectively. Conversely, when the population is restricted to patients 
with MELD 6-10, treatment before transplant is only cost-saving up to a treatment cost of 
$24,685 and treatment after transplant is only cost-saving up to $6,150. Fourth, there is no cost 
of transplantation that alters the results. Even if liver transplantation were to cost $0, treatment 
before transplant remains cost-effective. Fifth, there is no proportion of HCV-positive donors 
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that alters the results. Treatment before transplant prevents a sufficient number of transplants and 
deaths such that its cost-effectiveness is robust to a shrinking donor pool when excluding HCV-
positive allografts. Strictly from a perspective of total costs (irrespective of QALY), the no 
treatment becomes a cost-saving strategy when the proportion of HCV-positive donors exceeds 
17%. 
 
 The population EVPI was calculated to determine the value of further research on this 
question as a measure of uncertainty for these results. The population EVPI was calculated for 
the base-case, Child B and Child C patients, all at a WTP threshold of $100 000. The value of 
further research for the base-case is $185,806 and $556,808 and $12 million for Child B and C 
patients, respectively. 
 
Discussion 
 Evidence increasingly supports the widespread uptake of highly effective, safe treatments 
for chronic hepatitis C therapy.
1-4,10,23,24
 For clinicians and payers alike, a significant gap in the 
available data regards the timing of therapy for patients with Child B or C cirrhosis who are 
simultaneously at increased risk for death and liver transplantation. Prior decision analyses have 
established the cost-effectiveness of novel direct acting antiviral therapies for simulated cohorts 
of treatment naïve patients with HCV (with a range of generally early stage disease),
10,12
 patients 
with exclusively early fibrosis,
25,26
 noncirrhotic patients with genotype 2 or 3 HCV,
11
 and 
patients with recurrent HCV after liver transplantation.
27
 In this study of patients with 
decompensated liver disease utilizing clinical trial data, these findings demonstrate that treatment 
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with LDV-SOF and ribavrin is cost-effective from the societal perspective for patients with 
Child B or C cirrhosis related to genotype 1 or 4 HCV, particularly those with MELD > 13. 
 
 Microsimulations allow us recreate and test the outcomes of clinical trials in the context 
of uncertainty about the results by varying the input parameters – be it SVR, MELD score before 
therapy and quality of life – over a wide range of values. Specifically, our microsimulation 
generalizes the outcomes of from the SOLAR study by re-running the trial for 10 000 simulated 
patients with 10 000 separate trials for each patient using different permutations of the values of 
the clinical variables listed in Table 1. These data are therefore robust and extend the findings of 
prior literature in 4 main ways. First, we quantify the benefits of therapy for patients with 
decompensated cirrhosis across MELD scores and Child classes. No prior cost-effectiveness 
study has analyzed the impact of therapy on MELD scores and the risk of death or 
transplantation on the waiting list. It is likely that the key to our observed treatment cost-
effectiveness is the often significant reduction in MELD score after therapy which 
simultaneously leads to reductions in death as well as the need for liver transplantation. For these 
reasons, the baseline MELD among patients with decompensated cirrhosis after which treatment 
before transplant is the most cost-effective strategy is 13. An improvement in the MELD is 
inherently valuable for patients with MELD > 13 because MELD drives transplant (cost) at the 
same time as mortality. Accordingly, treatment before transplant is a dominant strategy when 
transplant occurs at early MELD (> 20) and sensitivity analyses show these findings to be robust 
at SVR roughly half of that observed (49.2%) and a cost of therapy roughly twice of that 
currently charged ($177,381). Similarly, there is no cost of transplantation at which another 
strategy becomes cost-effective because treatment before transplant provides substantial 
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incremental increases in most patients’ QALYs. Cost-effectiveness is determined by the cost for 
each additional QALY. In the case of treatment before transplant, it is both saves money (by 
reducing transplants) and improves and prolongs life (ie QALYs), making it a superior strategy 
largely independent of the costs of care. 
 
Second, in contrast to the prior decision analyses which rely entirely on published 
estimates for modelling, this study’s core strength is that major determinants of clinical decision 
making are derived from a clinical trial. For this reason, conditional variables such as SVR both 
before and after transplant, as well as the clinical impact of therapy (measured in changes in 
MELD score) reflect clinical experiences. Crucially, we model SVR from the ‘intention to treat,’ 
accounting for deaths on treatment. For this reason and others, we capture the fact that patients 
with Child C have lower SVR before or after transplant than Child B. Third, the EVPI analysis 
shows that given the magnitude of benefit as well as its robustness in a probabilistic sensitivity 
analysis, the value of further research on this topic is extremely limited. Fourth, we test the 
possibility that by treating patients with HCV prior to transplant, we contract the donor pool by 
foregoing transplantation with HCV+ donors. In a sensitivity analysis, we demonstrate that 
owing to the reduced risk of death or transplant as a function of generally lower MELD after 
therapy, there is no proportion of HCV+ donors at which the optimal treatment strategy changes 
from treatment before transplant. 
  
These data must be understood in the context of the study design. First, these data model 
outputs from SOLAR study which had notable exclusions, including patients with coinfections, 
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total bilirubin > 10 mg/dL and creatinine clearance <40 mL/min. These data cannot be 
generalized to those Child B and C subpopulations, likely including patients with MELD > 35.  
Second, the modelled benefits of SVR on QOL were modest and restricted to a 57% of the 
population which may underestimate the benefits of therapy.
6
 Similarly, the natural history of 
decompensated cirrhosis following SVR is not fully understood. We assigned the same MELD-
based risk of death and transplant to patients with and without SVR. Third, while a strength of 
this model is the use of input parameters from a clinical trial, it should be noted that some of the 
observed estimates are likely conservative relative to those from subsequent cohort studies (eg 
posttransplant SVR rates for Child C patients). 
28
 Fourth, we did not model the risk and impact of 
hepatocellular carcinoma (HCC) diagnoses and treatment in order to specifically answer 
questions specific to treatment for patients with decompensated cirrhosis. However, given that 
for patients with HCC time on the waitlist is the primary driver of transplantation, treatment 
therefore does not reduce the need for transplant.  
 
Finally, we modelled cost-effectiveness from the societal perspective. For the individual 
patient, however, a reduced risk of transplantation may or may not be preferable. Treatment of 
HCV may forestall MELD progression and the risk of decompensation. Accordingly, for patients 
with sufficiently poor waitlist QOL, stable reductions in MELD in the post-MELD era of 
transplant allocation could lead to the so-called ‘MELD Purgatory.’29 While we modelled 
changes in MELD following SVR, we could not model the probability of improved Child score 
after therapy, which could potentially impact QOL, independent of effects on MELD. The main 
results of SOLAR trial as well as ASTRAL-4 do suggest, however, that many patients 
experience improvements in Child-Pugh score.
3,30
 Therefore, treatment after transplant may be 
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desirable from the perspective of patients unwilling to accept the possibility of stable MELD in 
the setting of decompensated cirrhosis. Cost-effectiveness from the societal perspective relates 
entirely to the prolonged lives with higher QOL and lower costs (ie transplant). However, the 
individualized benefits of treatment may clash with this perspective and can only be reconciled 
in the context of the patient-doctor relationship. Some patients may benefit from transplant over 
treatment (avoid MELD purgatory) and some may benefit from early treatment.  
 
 In conclusion, these data support the cost-effectiveness of LDV/SOF and ribavirin in 
patients with Child B or C cirrhosis prior to transplantation from a societal perspective.  
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FIGURE LEGENDS 
Figure 1: Flowchart of Patient Evaluation By Strategy 
MELD = model for endstage liver disease. SVR = sustained virologic response 
Figure 2: A Simplified Depiction of the Microsimulation State-Transition Model 
Each station reflects the ‘health states’ for any given patient as the model progresses with each cycle. 
Multiple factors help determine whether a patient ‘transitions’ between states including their model for 
endstage liver disease score and whether they achieved a sustained virologic response. 
Figure 3: Change in MELD Scores after Treatment 
The changes in Model for Endstage Liver Disease (MELD) score after treatment are depicted, stratified 
by MELD score (> 15 or < 15) and Child Class (B or C).  
Figure 4: Cost-Acceptability Curves: Strategy Cost-Effectiveness by Willingness-to-Pay Threshold 
(WTP) 
Each microsimulation has been repeated with many samples from the input parameter distributions 
(10 000 for the base-case and 1,000 for each subgroup). For each strategy, at each WTP threshold, there is 
a variable probability (proportion of samples) that it is the most cost-effective. This figure details how the 
‘Treat Before Transplant’ strategy is the dominant strategy at all WTP thresholds > $100 000 for each 
disease strata (MELD 11-15, > 15, Child B or C) save for MELD 6-10. As treatment before transplant can 
reduce a given patient’s MELD score, it can reduce the risk of death (which increases the average 
QALYs) and transplantation (which reduces the average cost).  
MELD = Model for Endstage Liver Disease, QALY = quality adjusted life year 
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Figure 4 
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Table 1: Estimates of Test Performance and Disease Prevalence for the Model 
Transition 
Probabilities 
Probability(event)/other 
modifiers 
Estimate (distribution) Source 
Probability of 
Waitlist Death 
within 90 days 
MELD 6-10 0.019 (0.016-0.022) 
17
 
MELD 11-19 0.06 (0.05-0.07) 
MELD 20-29 0.20 (0.16-0.23) 
MELD  > 30 0.54 (0.44-0.62) 
Probability of 
Transplantation 
within 90 days 
MELD 6-15 0.024 (0.019-0.029) 
22
 MELD 16-30 0.39 (0.31-0.46) 
MELD >30 0.88 (0.70-1) 
Treatment 
Major Adverse Event 0.063 (0.050-0.076) 
3
 
SVR – Pre-Transplant Child B and 
C 
90.9% (80/88 subjects) 
Secondary 
analysis of 
SOLAR 
trial 
SVR – Child B (Pre) 88.2% (45/51 subjects) 
SVR – Child C (Post) 94.6% (35/37 subjects) 
SVR – Post-Transplant Child B and 
C 
91.8% (45/49 subjects) 
SVR – Child B (pre) 95.3% (41/43 subjects) 
SVR – Child C (post) 66.7% (4/6 subjects) 
Disease Progression 
Annual MELD  progression 
without treatment 
1.23 + 0.42 
31
 
Posttransplant 
Survival, year 1 0.86 (0.86-0.87) 
22
 
Annual mortality, > Year 2 0.066 (0.053-0.79) 
32
 
Graft Failure with HCV 0.08 (0.04 – 0.16) 33
 
Graft Failure without HCV 0.06 (0.03 – 0.12) 
Death in year after graft failure 0.21 (0.21-0.23) 
34
 Retransplantation after  
graft failure 
0.52 (0.50 – 0.52) 
Costs  
(2014 US Dollars) 
Details Estimate (Distribution) Source 
ledipasvir/sofosbuvir 
and ribavirin 
12 week course 95,523 
18
 
Decompensated 
Cirrhosis 
Annual costs of care 
16,263 (13, 011 – 
40,198) 
35,36
 
Transplant 
Annual costs of care (year 1) 
344,030  
(267,493 –344,030)* 37,38
 
Annual costs of care  
(> year 1) 
47,081 (42,277 – 
51,365) 
Death Minimum annual costs 
61,655 (38,866 – 
65,975) 
39,40
 
Utilities Details Estimate (Distribution) Source 
Child B/C Cirrhosis Utility per annum 0.60 (0.46 – 0.71) 37,41-44 
Posttransplant 
Utility per annum  (Year 1) 0.69 (0.55 – 0.78) 42 
Utility per annum  (> Year 1) 0.79 (0.62 – 0.79) 37,42,45 
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MELD = Model for endstage liver disease, SVR = sustained virologic response. * Sensitivity analyses assessed 
transplant costs from $0-344,030 
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Table 2: Main Results 
 
Average 
Overall Cost 
(USD) 
Incremental 
Cost (USD) 
Average 
Overall 
QALYs 
Incremental 
QALYs 
Cost per 
incremental 
QALY 
Base Case: Patients with Child B or C Cirrhosis Representative of the SOLAR Study 
Treat before 
transplant 354,560  2.31   
No treatment 356,824 2,264 2.15 -0.16 N/A 
Treat After 
Transplant 409,445 54,885 2.26 -0.04 N/A 
Patients with a MELD score 6-10 
No treatment 197,088  2.20   
Treat After 
Transplant 218,567 21,479 2.23 0.03 715,967 
Treat before 
transplant 245,724 48.636 2.57 0.38 127,989 
Patients with a MELD score 11-15 
No treatment 224,404  1.85   
Treat before 
Transplant 252,667 28,263 2.25 0.39 71,568 
Treat after 
transplant 254,323 29,920 1.91 0.06 541,705 
Patients with a MELD score > 15 
Treat before 
transplant 396,248  2.27   
No treatment 414,220 17,971 2.2 -0.07 N/A 
Treat After 
Transplant 477,720 81,471 2.35 0.08 1,047,623 
Patients with Child B Cirrhosis Alone 
No treatment 276,674  2.12   
Treat before 
transplant 278,194 1,519 2.4 0.28 5,470 
Treat After 
Transplant 314,412 37,738 2.19 0.07 521,568 
Patients with Child C Cirrhosis Alone 
No treatment 412,059  2.17   
Treat before 
transplant 412,914 854 2.28 0.11 8,103 
Treat After 
Transplant 474,986 62,927 2.26 0.08 749,225 
 
All incremental data reference a common baseline. Prices are in 2014 US dollars. Negative cost-
effectiveness ratios are not presented (hence n/a). MELD = model for endstage liver disease, 
QALY = quality adjusted life years, USD = US Dollars  
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Table 3: The MELD Score At the Time of Transplant Affects Treatment Cost-Effectiveness 
 
 
Average 
Overall Cost 
(USD) 
Incremental 
Cost (USD) 
Average 
Overall 
QALYs 
Incremental 
QALYs 
Cost per 
incremental 
QALY 
Hypothetical Region with High Transplant Rate at MELD >  20 
Treat before 
transplant 351,714  2.43   
No treatment 361,700 9,986 2.26 -0.16 N/A 
Treat After 
Transplant 414,010 62,295 2.38 -0.04 N/A 
Hypothetical Region with High Transplant Rate only at MELD >  30 
No treatment 177,943  1.63   
Treat Before 
Transplant 199,450 5,018 1.81 0.18 27,878 
Treat After 
transplant 182,961 21,507 1.68 0.05 430,140 
All incremental data reference a common baseline. Prices are in 2014 US dollars. Negative cost-
effectiveness ratios are not presented (hence n/a). MELD = model for endstage liver disease, 
QALY = quality adjusted life years, USD = US Dollars 
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